Karen Quillen

Summary

Affiliation: Boston University
Country: USA

Publications

  1. pmc Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
    Michael Walsh
    Departments of Medicine and Clinical Epidemiology and Biostatistics, Marian Wing, Division of Nephrology, McMaster University, St, Joseph s Hospital, 50 Charlton Ave East, Hamilton, ON L8S 4A6, Canada
    Trials 14:73. 2013
  2. pmc Granulocyte transfusions in severe aplastic anemia: an eleven-year experience
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Haematologica 94:1661-8. 2009
  3. pmc A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies
    Karen Quillen
    Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland, USA
    Transfusion 51:92-6. 2011
  4. pmc Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 49:513-8. 2009
  5. pmc The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 49:421-6. 2009
  6. doi request reprint Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection
    Karen Quillen
    Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, MA 02118, USA
    Pediatr Infect Dis J 27:357-8. 2008
  7. pmc Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome
    Karen Quillen
    Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland 02118, USA
    Transfusion 51:504-10. 2011
  8. doi request reprint A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis
    K Quillen
    Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 46:976-80. 2011
  9. ncbi request reprint Quality improvement to decrease specimen mislabeling in transfusion medicine
    Karen Quillen
    Department of Laboratory Medicine, Boston University Medical Center, Boston, Mass 02118, USA
    Arch Pathol Lab Med 130:1196-8. 2006
  10. pmc Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
    David C Seldin
    Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
    Blood 108:3945-7. 2006

Collaborators

Detail Information

Publications22

  1. pmc Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
    Michael Walsh
    Departments of Medicine and Clinical Epidemiology and Biostatistics, Marian Wing, Division of Nephrology, McMaster University, St, Joseph s Hospital, 50 Charlton Ave East, Hamilton, ON L8S 4A6, Canada
    Trials 14:73. 2013
    ..A randomized study of both plasma exchange and glucocorticoids is required to evaluate plasma exchange and oral glucocorticoid dosing in patients with AAV...
  2. pmc Granulocyte transfusions in severe aplastic anemia: an eleven-year experience
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Haematologica 94:1661-8. 2009
    ..Infections, particularly those caused by invasive fungi, are a major cause of death in patients with severe aplastic anemia. The purpose of this study was to analyze our experience with granulocyte transfusions in such patients...
  3. pmc A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies
    Karen Quillen
    Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland, USA
    Transfusion 51:92-6. 2011
    ..Hemolytic transfusion reactions (HTRs) can occur from ABO-incompatible platelet (PLT) transfusions. After a series of cases at our institution, a procedure to screen all plateletpheresis donors for high-titer ABO antibodies was implemented...
  4. pmc Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 49:513-8. 2009
    ..The short-term side effects of G-CSF are well studied, but the potential long-term effects of repeated G-CSF stimulation in unrelated volunteer granulocyte donors have not been reported...
  5. pmc The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience
    Karen Quillen
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 49:421-6. 2009
    ....
  6. doi request reprint Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection
    Karen Quillen
    Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston, MA 02118, USA
    Pediatr Infect Dis J 27:357-8. 2008
    ..The prevalence of anticeftriaxone antibody was 12.5% (8 of 64). Two of these 8 patients with the antibody experienced hemolysis; 1 case was fatal...
  7. pmc Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome
    Karen Quillen
    Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland 02118, USA
    Transfusion 51:504-10. 2011
    ....
  8. doi request reprint A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis
    K Quillen
    Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    Bone Marrow Transplant 46:976-80. 2011
    ..Three patients died of progressive disease at 1-2 years. In conclusion, one-third of patients with AL amyloidosis who relapse after HDM/SCT can achieve HCR with a second SCT...
  9. ncbi request reprint Quality improvement to decrease specimen mislabeling in transfusion medicine
    Karen Quillen
    Department of Laboratory Medicine, Boston University Medical Center, Boston, Mass 02118, USA
    Arch Pathol Lab Med 130:1196-8. 2006
    ..Proper specimen identification and labeling is a critical preanalytic step in pretransfusion compatibility testing...
  10. pmc Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
    David C Seldin
    Section of Hematology Oncology, Boston University Medical Center, 650 Albany St, Boston, MA 02118, USA
    Blood 108:3945-7. 2006
    ....
  11. doi request reprint Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
    Saulius Girnius
    Amyloid Treatment and Research Program, Boston University School of Medicine, Boston, MA 02118, USA
    Ann Hematol 89:579-84. 2010
    ..Hematologic relapses occurred in 60% of patients at a median of 1 year after HDM/SCT. In conclusion, HDM/SCT can prolong overall survival in patients with MM/AL who are eligible to receive it...
  12. ncbi request reprint Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
    David C Seldin
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
    Blood 104:1888-93. 2004
    ..Thus, treatment of AL amyloidosis patients with HDM/SCT produces measurable and sustained improvements in quality of life, particularly in those patients who achieve hematologic CR...
  13. pmc Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review
    Martin Tam
    Graduate Medical Sciences Division, Boston University School of Medicine, Boston, Massachusetts, USA
    Amyloid 16:103-7. 2009
    ..A literature review of spontaneous liver rupture in patients with amyloidosis is presented...
  14. pmc Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients
    Maria Teresa Cibeira
    Amyloid Treatment and Research Program, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 118:4346-52. 2011
    ..9 years, respectively. Thus, treatment of selected AL patients with HDM/SCT resulted in a high organ response rate and long OS, even for those patients who did not achieve CR...
  15. pmc Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease
    Saulius Girnius
    Department of Medicine, Boston University School of Medicine, Boston University School of Public Health, Boston, MA, USA
    Haematologica 94:1029-32. 2009
    ..In conclusion, hepatic disease improves in almost 2/3 patients treated with high-dose intravenous melphalan and autologous stem cell transplantation who have a complete or partial hematologic response to treatment...
  16. pmc Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
    Vaishali Sanchorawala
    Stem Cell Transplantation Program of the Section of Hematology Oncology, Boston University School of Medicine, Boston, MA 02118, USA
    Blood 110:3561-3. 2007
    ..001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR...
  17. pmc Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions
    Jennifer Daniel-Johnson
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, and the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Transfusion 49:1845-9. 2009
    ..Reported cases have involved group O donors. Two cases of PLT-mediated HTRs associated with the same group A plateletpheresis component, collected from a donor taking high doses of probiotics are reported...
  18. ncbi request reprint High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study
    Martha Skinner
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Ann Intern Med 140:85-93. 2004
    ..AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective...
  19. doi request reprint A massive transfusion protocol incorporating a higher FFP/RBC ratio is associated with decreased use of recombinant activated factor VII in trauma patients
    Josenia N M Tan
    Dept of Pathology and Laboratory Medicine, Boston University Medical Center, MA 02118, USA
    Am J Clin Pathol 137:566-71. 2012
    ..An MTP incorporating a higher FFP/RBC ratio of 1:1 to 1:2 is associated with decreased use of blood components and may obviate the need for rFVII...
  20. doi request reprint Prevalence of RhD variants, confirmed by molecular genotyping, in a multiethnic prenatal population
    Dehua Wang
    Department of Pathology and Laboratory Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA 02118, USA
    Am J Clin Pathol 134:438-42. 2010
    ..2% of our multiethnic population. Consideration of patients' ethnic background and close cooperation between pathologists and obstetric providers facilitate optimal prenatal care in these cases...
  21. ncbi request reprint Effect of hydroxyurea on immature reticulocyte fraction in sickle cell anemia
    Robert Bagdasaryan
    Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, Rhode Island, USA
    Lab Hematol 13:93-7. 2007
    ..4), suggesting continuous bone marrow stimulation in SS-HU patients in response to tissue hypoxia. The possible underlying physiological mechanisms are discussed...
  22. ncbi request reprint A novel sickle hemoglobin: hemoglobin S-south end
    Hong Yuan Luo
    Hemoglobin Diagnostic Reference Laboratory, Boston Medical Center, Boston, Massachusetts, USA
    J Pediatr Hematol Oncol 26:773-6. 2004
    ..Furthermore, the variant hemoglobin mimics Hb A on high-pressure liquid chromatography, and its identity is not easily diagnosed. A succinct review of variant sickle hemoglobins is also presented...